Tioguanine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tioguanine
Tioguanine
Summary
All of the TxGNN model’s candidates for Tioguanine (score ≥ 0.99) that can be traced to a source are already known uses, so there is currently no new predicted indication. The one known use is recorded as a relation in the knowledge graph; no approval was matched for it in this analysis.
Quick overview
| Item | Content |
|---|---|
| Known uses among model candidates | 1 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| myeloid leukemia |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 1233X | Lanvis | Tablet 40 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (thiopurine antimetabolite) |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Full blood count (with differential), liver function tests, bilirubin and renal function (to be confirmed against the PI) |
| Handling Protection | Follow local cytotoxic drug handling requirements |
Safety Considerations
- Contraindication-related conditions (knowledge-graph data, not label text): liver disease, drug-induced liver injury, cholestasis (including benign recurrent and familial intrahepatic forms), gallbladder disease, hyperbilirubinaemia (including hereditary forms and Gilbert syndrome), thrombocytopenia, neutropenia, leukopenia, agranulocytosis, anaemia (including macrocytic anaemia) and hyperuricaemia.
- Drug Interactions: 100 interactions were identified, and the 20 listed in the data are all rated Moderate. They include:
- Aminosalicylates: mesalazine, balsalazide, olsalazine, sulfasalazine
- Antidiabetic drugs: acarbose, pioglitazone, rosiglitazone
- Statins: rosuvastatin, simvastatin
- Antibiotics: clarithromycin, minocycline, levofloxacin
- Others: bupropion, chenodeoxycholic acid, oxandrolone, oxymetholone, naltrexone, orlistat, clotrimazole, nicotinamide
The label warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for authoritative safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.